SynthesisBMC public health2023
Prevalence and variability of HIV/AIDS-associated neurocognitive impairments in Africa: a systematic review and meta-analysis.
Synthesis in BMC public health, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Clinical and behavioral predictors of HIV-associated neurocognitive disorder among people with HIV who use substances: a secondary analysis of the HOPE trial.Journal of neurovirology · 2026Trial
- Changes in cognitive performance following combined CogSMART-SA and BrainHQ interventions: a pilot study.BMC neurology · 2026Trial
- HAND in Africa: prevalence, diagnostic challenges and the search for objective markers.Journal of neurovirology · 2026Review
- Distinct acute and chronic brain health phenotypes among people living with HIV in a Ugandan clinical cohort: a comorbidity network analysis.Research square · 2026Article
- Gaps in Testing for HIV in Individuals with Neurological Conditions: Implementation Strategies to Improve HIV Screening and Early Diagnosis.Current HIV/AIDS reports · 2026Review
- Cognitive and sensorimotor impairments in virally suppressed people with and without HIV in Uganda: Associations with neurofilament light chain as a biomarker of neuronal injury.Journal of neurovirology · 2026Article
- Article
- Review
- Diagnostic accuracy of IHDS and MoCA in screening for HIV-associated neurocognitive disorders among adults living with HIV in Ethiopia.International journal of mental health systems · 2026Article
- Cognitive impairment is associated with poorer oral health in people with HIV: evidence from a pilot study.Quintessence international (Berlin, Germany : 1985) · 2026Article
- HIF-1 Targeting Intervention Renders Protection From Alzheimer's-Like Pathology in a Humanized Mice Model of HIV Infection.Journal of extracellular vesicles · 2025Article
- Dual trajectories of serum brain-derived neurotrophic factor and cognitive function in people living with HIV.Scientific reports · 2025Observational
- Dementia prevalence and risk factors in people with and without HIV in Malawi: A medical record review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Generating fair, reliable, and accurate neuropsychological test norms for people with HIV in a low- or middle-income country.Journal of neurovirology · 2025Article
- Assessing neurocognitive functioning among adults ageing with and without HIV at the Kenyan Coast: measurement issues and correlates.Frontiers in aging neuroscience · 2025Article
- Article
- HIV-associated neurocognitive disorders in Africa: challenges, peculiarities, and future directions.AIDS research and therapy · 2024Review
- Article
- The Association Between Serum Mature and Precursor Brain-Derived Neurotrophic Factor and Neurocognitive Function in People With Human Immunodeficiency Virus: A Longitudinal Study.Open forum infectious diseases · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHIV/AIDS-associated neurocognitive impairments negatively affect treatment adherence, viral load suppression, CD4 count, functionality, and the overall quality of life of people with seropositive status. However, huge variability is observed across primary studies regarding the prevalence and determinants of neurocognitive impairment in people with HIV/AIDS. This systematic review and meta-analysis sought to determine the pooled prevalence of neurocognitive impairment and identify factors contributing to variations in its estimate among people living with HIV/AIDS in Africa.
methodsA comprehensive literature search of scientific databases (Medline/PubMed, SCOPUS, Web of Science, PsycINFO, and EMBASE) was performed from inception onward. Google and Google Scholar were also searched for grey literature. Research articles available until July 15, 2022 were included. We used STATA-version 14 statistical software for analysis. A random effect model was executed to pool the reported prevalence of neurocognitive impairments. Subgroup analysis was done to show variations in the prevalence of neurocognitive impairments and factors that might contribute to these variations.
resultsA literature search resulted in 8,047 articles. After the removal of duplications and thorough evaluation, a total of 49 studies were included in the meta-analysis. The prevalence of HIV/AIDS-associated neurocognitive impairments was highly variable across studies, ranging from 14% to 88%, yielding the pooled prevalence of HIV/AIDS-associated neurocognitive impairment to be 46.34% [95% CI (40.32, 52.36)] and I
conclusionsA large proportion of people living with HIV/AIDS in Africa have HIV/AIDS-associated neurocognitive impairment. This illustrates the need to establish practical approaches to early identification and effective control of HIV/AIDS-associated neurocognitive impairments. However, there were variabilities in the reported prevalence of HIV/AIDS-associated neurocognitive impairments across studies. This further demonstrates the need to have consistent measurement approaches.
trial registrationPROSPERO 2022, "CRD42020166572".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.